Oppenheimer Holdings Inc. set a $70.00 target price on Prothena Co. PLC (NASDAQ:PRTA) in a research note issued to investors on Thursday. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other equities analysts also recently weighed in on the stock. Nomura started coverage on shares of Prothena Co. PLC in a research note on Wednesday, March 1st. They set a buy rating for the company. Zacks Investment Research raised shares of Prothena Co. PLC from a hold rating to a buy rating and set a $55.00 target price for the company in a research note on Tuesday, January 3rd. Instinet began coverage on shares of Prothena Co. PLC in a report on Wednesday, March 1st. They issued a buy rating and a $87.00 price target for the company. SunTrust Banks, Inc. began coverage on shares of Prothena Co. PLC in a report on Tuesday, December 20th. They issued a buy rating and a $75.00 price target for the company. Finally, Wedbush restated an outperform rating and issued a $77.00 price target on shares of Prothena Co. PLC in a report on Wednesday, February 15th. Twelve equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and a consensus price target of $75.09.
Prothena Co. PLC (NASDAQ:PRTA) traded down 1.43% during mid-day trading on Thursday, reaching $53.14. The company had a trading volume of 159,405 shares. The company’s 50 day moving average is $53.15 and its 200 day moving average is $53.66. Prothena Co. PLC has a 52-week low of $33.53 and a 52-week high of $68.18. The stock’s market capitalization is $1.86 billion.
Prothena Co. PLC (NASDAQ:PRTA) last announced its earnings results on Tuesday, February 14th. The biotechnology company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by $0.29. Prothena Co. PLC had a negative return on equity of 32.65% and a negative net margin of 11,365.41%. The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $5.35 million. During the same period in the prior year, the business earned ($0.76) EPS. Prothena Co. PLC’s quarterly revenue was down 35.5% on a year-over-year basis. Equities analysts predict that Prothena Co. PLC will post ($5.07) earnings per share for the current year.
WARNING: This piece of content was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/04/21/prothena-co-plc-prta-given-a-70-00-price-target-at-oppenheimer-holdings-inc-updated.html.
In other news, insider Karin L. Walker sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $52.25, for a total value of $261,250.00. Following the sale, the insider now owns 3,000 shares of the company’s stock, valued at $156,750. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Tran Nguyen purchased 1,000 shares of the stock in a transaction dated Thursday, March 9th. The stock was acquired at an average cost of $51.32 per share, for a total transaction of $51,320.00. Following the transaction, the chief financial officer now owns 3,200 shares of the company’s stock, valued at $164,224. The disclosure for this purchase can be found here. Insiders own 3.70% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. raised its stake in Prothena Co. PLC by 26.4% in the third quarter. PNC Financial Services Group Inc. now owns 2,740 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 573 shares during the period. HL Financial Services LLC acquired a new stake in Prothena Co. PLC during the third quarter valued at about $206,000. Aperio Group LLC purchased a new stake in Prothena Co. PLC during the third quarter worth $210,000. BNP Paribas Arbitrage SA raised its stake in Prothena Co. PLC by 26.0% in the third quarter. BNP Paribas Arbitrage SA now owns 5,091 shares of the biotechnology company’s stock worth $305,000 after buying an additional 1,052 shares during the period. Finally, Focused Wealth Management Inc raised its stake in Prothena Co. PLC by 7.8% in the fourth quarter. Focused Wealth Management Inc now owns 6,250 shares of the biotechnology company’s stock worth $307,000 after buying an additional 450 shares during the period.
Prothena Co. PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Co. PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Co. PLC and related companies with MarketBeat.com's FREE daily email newsletter.